Armata Pharmaceuticals, Inc. (NYSEAMERICAN:ARMP) Short Interest Update

Armata Pharmaceuticals, Inc. (NYSEAMERICAN:ARMP) was the recipient of a large drop in short interest in March. As of March 31st, there was short interest totalling 3,600 shares, a drop of 53.2% from the March 15th total of 7,700 shares. Based on an average trading volume of 15,300 shares, the short-interest ratio is presently 0.2 days. Approximately 0.0% of the shares of the stock are short sold.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reiterated a “buy” rating and set a $7.00 target price on shares of Armata Pharmaceuticals in a research report on Thursday, December 19th.

Armata Pharmaceuticals Trading Up 7.0 %

Shares of Armata Pharmaceuticals stock traded up $0.08 during trading on Wednesday, hitting $1.23. 3,075 shares of the stock traded hands, compared to its average volume of 11,847. The firm has a market capitalization of $44.50 million, a PE ratio of -0.75 and a beta of 0.87. Armata Pharmaceuticals has a 52 week low of $0.90 and a 52 week high of $3.45.

Armata Pharmaceuticals Company Profile

Armata Pharmaceuticals, Inc, a clinical-stage biotechnology company, focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company's product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; AP-PA02 for Pseudomonas aeruginosa; and AP-PA03 for the treatment of pneumonia.